8-K: QuidelOrtho Reinstates 2024 Guidance After Solid Q3 Performance

QuidelOrtho announced its third quarter 2024 financial results, reinstating its full-year 2024 financial guidance and highlighting cost-saving initiatives.

Summary

• QuidelOrtho reported a total revenue of $727 million for the third quarter of 2024, a slight decrease from $744 million in the same period last year, primarily due to reduced COVID-19 and influenza revenue.
• Recurring revenue was $598 million, with no significant change in constant currency when excluding COVID-19 and U.S. Donor Screening revenue.
• Labs revenue saw a growth of 4% as reported and 5% in constant currency.
• GAAP operating expenses decreased by $13 million to $242 million, while non-GAAP operating expenses decreased by $17 million to $232 million.
• The company reported a GAAP net loss margin of (3%) and a GAAP operating margin of 2%.
• Adjusted EBITDA margin increased to 23.5%, up 80 basis points from the previous year.
• GAAP net cash provided by operating activities was $118 million, and adjusted free cash flow was $120 million.
• The company has reinstated its full-year 2024 financial guidance, projecting total revenues between $2.75 and $2.80 billion, adjusted EBITDA between $530 and $550 million, and adjusted diluted EPS between $1.69 and $1.91.
• QuidelOrtho is targeting $100 million in annualized cost savings.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue decreased slightly, the company is showing progress in cost management, margin improvement, and has reinstated its full-year guidance. The leadership changes are also a positive sign.

Positives

• The company successfully reduced operating expenses, both on a GAAP and non-GAAP basis.
• Adjusted EBITDA margin improved by 80 basis points, indicating improved profitability.
• The company generated strong cash flow from operations and adjusted free cash flow.
• QuidelOrtho has reinstated its full-year 2024 financial guidance, demonstrating confidence in its performance.
• The company is making progress on its cost-saving initiatives, targeting $100 million in annualized savings.
• The leadership team has been strengthened with the addition of a new Chief Technology Officer and Chief Human Resources Officer.

Negatives

• Total revenue decreased slightly compared to the same quarter last year, primarily due to lower COVID-19 and influenza revenue.
• GAAP net loss for the quarter was $20 million, compared to a $13 million loss in the prior year period.
• GAAP operating income decreased to $15 million from $26 million in the prior year period.
• GAAP diluted loss per share was ($0.30), compared to ($0.19) in the prior year period.
• Third quarter results included $37 million in integration-related charges.

Risks

• The company faces fluctuations in demand for both respiratory and non-respiratory products.
• Supply chain, production, logistics, distribution, and labor disruptions could impact operations.
• Challenges and costs associated with integrating the merger of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc remain.
• Macroeconomic, geopolitical, market, business, competitive, and regulatory factors could affect the business.
• The company's forward-looking statements are subject to significant known and unknown risks and uncertainties.

Future Outlook

The company has reinstated its full-year 2024 financial guidance and is focused on achieving $100 million in annualized cost savings. They also plan to realize incremental cost savings in the future.

Management Comments

• Brian J. Blaser, President and Chief Executive Officer, stated that the company's strategic priorities and focus on customers, business growth, and margin improvement are gaining traction.
• Joseph Busky, Chief Financial Officer, noted that the decision to reinstate full-year financial guidance reflects solid performance in the first nine months of the year and increased visibility into the impact of cost-saving initiatives.

Industry Context

This announcement reflects the ongoing challenges and adjustments in the diagnostics industry, particularly with the decline in COVID-19 related revenues. The company's focus on cost savings and operational efficiency is a common theme in the current economic environment. The company is also focusing on non-respiratory revenue streams.

Comparison to Industry Standards

• QuidelOrtho's performance can be compared to other in-vitro diagnostics companies such as Abbott Laboratories, Roche, and Danaher.
• While QuidelOrtho experienced a slight revenue decrease, other companies in the sector have also seen fluctuations in revenue due to changing demand for COVID-19 testing.
• The company's adjusted EBITDA margin of 23.5% is a key metric to compare against industry peers, with some companies reporting higher margins and others lower.
• The focus on cost savings and efficiency is a common strategy across the industry, as companies adapt to the post-pandemic environment.
• QuidelOrtho's growth in Labs revenue is a positive sign, as this segment is a key driver for many diagnostics companies.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results and the reinstated guidance.
• Employees may be affected by the ongoing cost-saving initiatives and organizational changes.
• Customers will benefit from the company's focus on delivering high-quality products and services.
• Suppliers may be impacted by the company's cost-saving measures.
• Creditors will be interested in the company's cash flow and debt management.

Next Steps

• The company will hold a conference call to discuss the financial results.
• QuidelOrtho will continue to focus on cost-saving initiatives and business efficiency.
• The company will continue to strengthen its leadership team and align the organization for improved effectiveness.

Key Dates

Keywords

financial results, in-vitro diagnostics, revenue, EBITDA, cost savings, guidance, operating expenses, adjusted EPS, recurring revenue, labs revenue